Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
727.4 INR | +1.06% | +5.74% | +33.29% |
05-03 | Jubilant Pharmova Appoints CEO for Radiopharma Business | MT |
04-25 | Jubilant Pharmova Subsidiary's Canadian Manufacturing Unit Gets Five Observations from US FDA | MT |
Sales 2022 | 61.3B 736M 1B | Sales 2023 | 62.82B 754M 1.03B | Capitalization | 44.42B 533M 726M |
---|---|---|---|---|---|
Net income 2022 | 4.14B 49.71M 67.68M | Net income 2023 | -610M -7.33M -9.97M | EV / Sales 2022 | 1.37 x |
Net Debt 2022 | 22.03B 265M 360M | Net Debt 2023 | 26.44B 318M 432M | EV / Sales 2023 | 1.13 x |
P/E ratio 2022 |
14.9
x | P/E ratio 2023 |
-72.8
x | Employees | 5,778 |
Yield 2022 |
1.29% | Yield 2023 |
1.79% | Free-Float | 36.33% |
1 day | +1.06% | ||
1 week | +5.74% | ||
Current month | +8.08% | ||
1 month | +3.68% | ||
3 months | +19.98% | ||
6 months | +67.35% | ||
Current year | +33.29% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 46 | 17-05-22 | |
Chief Executive Officer | 37 | 17-05-22 | |
Arvind Chokhany
DFI | Director of Finance/CFO | 52 | 21-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 67 | 81-12-31 | |
Chairman | 71 | 78-06-20 | |
Chief Executive Officer | 46 | 17-05-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 4 M€ | -4.41% | - | |
0.00% | 34 M€ | +3.87% | - | |
0.00% | 112 M€ | +5.41% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-18 | 727.4 | +1.06% | 936 |
24-05-17 | 719.8 | +0.01% | 23,460 |
24-05-16 | 719.8 | +0.55% | 36,805 |
24-05-15 | 715.8 | +4.09% | 32,406 |
24-05-14 | 687.7 | -0.04% | 18,512 |
Delayed Quote Bombay S.E., May 18, 2024 at 12:08 am
More quotes1st Jan change | Capi. | |
---|---|---|
+33.29% | 1.37B | |
+32.09% | 694B | |
+29.39% | 593B | |
-1.34% | 371B | |
+20.34% | 331B | |
+7.39% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.49% | 169B |
- Stock Market
- Equities
- JUBLPHARMA Stock